Tested Applications
| Positive WB detected in | MCF-7 cells, HeLa cells |
| Positive IHC detected in | human stomach cancer tissue, mouse stomach tissue, rat stomach tissue, rat liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | NIH/3T3 cells, A549 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:250-1:1000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
21325-1-AP targets STARD13 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag15012 Product name: Recombinant human STARD13 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 113-393 aa of BC046563 Sequence: LDVNFQRKKGDDSDEEDLCISNKWTFQRTSRRWSRVDDLYTLLPRGDRNGSPGGTGMRNTTSSESVLTDLSEPEVCSIHSESSGGSDSRSQPGQCCTDNPVMLDAPLVSSSLPQPPRDVLNHPFHPKNEKPTRARAKSFLKRMETLRGKGAHGRHKGSGRTGGLVISGPMLQQEPESFKAMQCIQIPNGDLQNSPPPACRKGLPCSGKSSGESSPSEHSSSGVSTPCLKERKCHEANKRGGMYLEDLDVLAGTALPDAGDQSRMHEFHSQENLVVHIPKDH Predict reactive species |
| Full Name | StAR-related lipid transfer (START) domain containing 13 |
| Calculated Molecular Weight | 1113 aa, 125 kDa |
| Observed Molecular Weight | 125 kDa |
| GenBank Accession Number | BC046563 |
| Gene Symbol | STARD13 |
| Gene ID (NCBI) | 90627 |
| RRID | AB_2878840 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9Y3M8 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for STARD13 antibody 21325-1-AP | Download protocol |
| IHC protocol for STARD13 antibody 21325-1-AP | Download protocol |
| WB protocol for STARD13 antibody 21325-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The STARD13 Polyclonal antibody (Cat# 21325-1-AP) has 5 citations published in Cell Mol Biol Lett, Life Sciences, Biological Procedures Online, Endocrine, and Environmental Toxicology. The research fields span colorectal cancer metastasis, pancreatic cancer, hepatocellular carcinoma, papillary thyroid carcinoma, and doxorubicin-induced cardiotoxicity. Applications cited include Western blot and immunohistochemistry in human, mouse, and rat samples.
| Species | Application | Title |
|---|---|---|
Cell Mol Biol Lett LncRNA-like MMP14 RNA facilitates colorectal cancer metastasis by suppressing H3K27cr at the STARD13 promoter region. | ||
Life Sci Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis. | ||
Biol Proced Online Circ_0003570 Suppresses the progression of hepatocellular carcinoma through miR-182-5p/STARD13 regulatory axis | ||
Endocrine Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma
| ||
Environ Toxicol MiR-125b enhances doxorubicin-induced cardiotoxicity by suppressing the nucleus-cytoplasmic translocation of YAP via targeting STARD13. |
